ArticleNucleic acids research2025
The Epstein-Barr virus EBNA1 protein binds to G-quadruplexes in its own mRNA hence controlling its expression and immune evasion of the virus.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- EBNA1 inhibitors reveal CDC7 and POU2F1 as direct functional targets in EBV epithelial cancers.mBio · 2026Article
- Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation.NPJ vaccines · 2026Review
- RNA G-quadruplexes in oncogene regulation and as emerging targets for cancer therapy.Cell communication and signaling : CCS · 2026Review
- Mechanisms of and mitigating strategies for cellular immune responses to CRISPR-associated nucleases in genome editing therapy.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The oncogenic Epstein-Barr virus (EBV) evades the immune system but has an Achilles heel: its genome maintenance protein (GMP) EBNA1, which is essential for viral genome replication, but also highly antigenic. Hence, the virus evolved a mechanism to limit the translation of EBNA1 mRNA to the minimum level which allows EBNA1 to fulfil its essential function while minimizing production of EBNA1-derived antigenic peptides. This mechanism involves the binding of the arginine-glycine-rich (RGG) motif of nucleolin (NCL), a host protein, to RNA G-quadruplexes (rG4) of the viral EBNA1 mRNA. This binding is dependent on arginine methylation of NCL RGG. EBNA1 contains two RGG motifs suggesting it could also be involved in this mechanism. Here we show that EBNA1 binds directly to rG4 of its own mRNA and limits its own expression, depending on its RGG motifs and their arginine methylation. Furthermore, EBNA1 and NCL cooperate to bind to rG4 of EBNA1 mRNA. As the GMP function of EBNA1 has been previously associated to its ability to bind RNA in an rG4-dependent manner, our results suggest the existence of a ternary EBNA1/NCL/EBNA1 mRNA protein/RNA complex that serves for both EBNA1 GMP function and capacity to auto-limit its expression to evade the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.